Quoting Amgen founder George Ratham, the podcast guest emphasizes that a true biotech company must "walk through the valley of death"—experiencing near-bankruptcy multiple times. This trial by fire is not a sign of failure but a necessary process for building the character required for ultimate success.
Related Insights
The initial period of struggle and repeated failures, while painful, is what forges a resilient team and a strong, frugal company culture. These early hardships create shared experiences that define the company's DNA for years to come.
The CEO of Resolution Therapeutics views cell therapy development through the lens of boxing. He emphasizes that just as a boxer must get up after being hit, a leader in this volatile field must possess the resilience to absorb constant setbacks, stay focused, and keep moving the company forward.
Founder Sean Nelson reframes Chapter 11 bankruptcy not as a failure, but as an invaluable, real-world education. It provided a raw understanding of contracts, leases, and high-stakes decision-making that is impossible to learn academically. This crucible experience ultimately made him a more resilient and knowledgeable leader.
VCs can handle pivots and financial struggles. Their primary nightmare is a founder who quits. A startup's ultimate survival hinges on the founder's psychological resilience and refusal to give up, not just market or product risk.
Unlike software startups that can "fail fast" and pivot cheaply, a single biotech clinical program costs tens of millions. This high cost of failure means the industry values experienced founders who have learned from past mistakes, a direct contrast to Silicon Valley's youth-centric culture.
CellSci CEO Gerd Kirsten, a lawyer and financier, argues his primary function is protecting the company from market manipulation. He contends that his law and finance background has been more critical for survival than scientific expertise, which is useless without funding.
The path for biotech entrepreneurs is a long slog requiring immense conviction. Success ("liftoff") isn't just a clinical trial result, but achieving self-sustaining profitability and growth. This high bar means founders may need to persevere through years of market indifference and financing challenges.
While success is celebrated publicly, some of the best leadership happens privately when a CEO makes the tough, candid call to shut down a program or company due to unfavorable data. This "truth-seeking" decision, often against their personal interest, is a hallmark of excellence.
After two major clinical trial failures caused Fibrogen's market cap to fall from $5.5B to under $200M, the CEO executed a radical survival plan. He reduced headcount from 325 to about 50 and negotiated out of a crippling $90M lease to secure the company's future.
The industry over-celebrates financial winners. Equal praise should be given to leaders who, despite poor financial outcomes, successfully pioneer new scientific ground or persevere to get a drug approved for a high unmet need. Their work provides crucial groundwork for future successes.